Validates the use of the RAPID score for predicting mortality in pleural infections, directly informing the management of patients undergoing pleural interventions like chest tubes and medical thoracoscopy.
Abstract
Introduction: Intrapleural fibrinolytic therapy, involving the sequential administration of DNase and tissue plasminogen activator (tPA), is a key component in the management of pleural infections. This approach has been shown to reduce hospital length of stay and the need for surgical intervention. However, it remains unclear whether these agents are pharmaceutically compatible for concurrent administration. This study investigated the compatibility of DNase and tPA when mixed together.
Methods: We prepared the following combinations of tPA (Actilyse, Boehringer Ingelheim B.V.) and DNase (Pulmozyme, Roche Nederland B.V.): undiluted (10 mg tPA + 5 mg DNase), diluted in 50 mL saline, and diluted in 500 mL saline. Control solutions containing only tPA, only DNase, or only saline were also prepared. Physical stability was assessed by visual inspection for particulate formation, haze, precipitation, color change, or gas evolution. Physical compatibility was evaluated by measuring pH at baseline, 2 h, and 4 h post-preparation, at both room temperature and 40°C. Incompatibility was defined as a mean absolute pH change greater than 1 unit over time.
Results: All tested solutions remained physically compatible across all time points, dilutions, and temperatures.
Conclusion: Our findings demonstrate that tPA and DNase are pharmaceutically compatible when mixed and diluted in normal saline. This supports the feasibility of concurrent intrapleural administration, which may reduce labor intensity, improve protocol adherence, and lower the risk of iatrogenic infections in patients with pleural infections.
Keep reading
N opens the next oneUltrasound estimation of pleural fluid volume is a core procedural skill for thoracentesis and chest tube placement, making this directly relevant to IP practice.
Directly impacts pleural management and staging by maximizing the diagnostic yield of routine thoracentesis for molecular testing in malignancy.
Pleural fluid obtained during thoracentesis or medical thoracoscopy should be preserved for cfDNA molecular testing when tissue is limited.
Relevant to pleural disease management and post-procedural care of trapped or non-expandable lungs.
Provides useful risk stratification tools for managing secondary spontaneous pneumothorax patients who often require IP intervention.